Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
VERAXA has received Scientific Advice from the Paul-Ehrlich-Institute providing an initial derisking of the development path of its BiTAC-TCE program.
-
VERAXA Biotech initiates a collaboration with Ardigen SA to optimize cancer target pair selection for growing BiTAC® pipeline.
-
VERAXA Biotech AG today announced the appointment of Carl von Halem as as Interim Chief Financial Officer.
-
VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”) today provided a company and pipeline update.
-
VERAXA Biotech announces further progress with lead BiTAC® T-cell engager (BiTAC-TCE) program, initiates cell line development with ATUM.